Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...
Sonrotoclax, a BCL2 inhibitor, received FDA breakthrough therapy designation for relapsed or refractory mantle cell lymphoma, indicating its potential to transform patient outcomes. The drug is ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417 ...
Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne to participate in Project Orbis ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results